Literature DB >> 9533936

Macrophage-stimulating protein and its receptor in non-small-cell lung tumors: induction of receptor tyrosine phosphorylation and cell migration.

C G Willett1, M H Wang, R L Emanuel, S A Graham, D I Smith, V Shridhar, D J Sugarbaker, M E Sunday.   

Abstract

Previously, we identified macrophage-stimulating protein (MSP) as being expressed during hamster lung injury induced by nitrosamine carcinogens. Transient, generalized epithelial-cell hyperplasia during the preneoplastic period, and eventually nonneuroendocrine (non-NE) lung tumors, are known to develop in these nitrosamine-treated hamsters. We wished to test the hypothesis that MSP and its tyrosine kinase receptor, RON, might represent an autocrine/paracrine system involved in the pathogenesis of human nonneuroendocrine lung tumors, the non-small-cell carcinomas (NSCLCs). We found that this occurred in a paracrine fashion in three of eight primary human NSCLCs that expressed messenger RNA (mRNA) for MSP at high levels in histologically normal lung adjacent to the tumor, but not in the primary tumor, together with mRNA for RON in both normal and tumor tissue. MSP and RON could also constitute an autocrine/paracrine system in human NSCLC cell lines: five of 16 cell lines (squamous and adenosquamous) expressed both MSP and RON; and an additional five of 16 cell lines expressed RON without detectable MSP. Although three cases of primary squamous-cell carcinomas expressed MSP (two of three in the tumor and one of three in nonneoplastic lung), mRNA for RON was not detectable in these cases. RON was functional in all tested RON mRNA-positive cell lines, with exogenous MSP inducing RON-mediated tyrosine phosphorylation. Treatment of a RON-positive adenosquamous carcinoma cell line with MSP additionally resulted in increased motility in a cell-migration assay, suggesting that MSP might promote cell migration of some NSCLCs. In conclusion, MSP and RON might represent an autocrine/paracrine system involved in the pathogenesis of lung cancer, although the nature of the biologic responses in different cell types might vary considerably.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9533936     DOI: 10.1165/ajrcmb.18.4.2978

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  14 in total

1.  Macrophage stimulating protein is a novel neurotrophic factor.

Authors:  M C Stella; A Vercelli; M Repici; A Follenzi; P M Comoglio
Journal:  Mol Biol Cell       Date:  2001-05       Impact factor: 4.138

2.  Macrophage-stimulating protein differently affects human alveolar macrophages from smoker and non-smoker patients: evaluation of respiratory burst, cytokine release and NF-kappaB pathway.

Authors:  Gabriele Gunella; Claudio Bardelli; Angela Amoruso; Ilario Viano; Piero Balbo; Sandra Brunelleschi
Journal:  Br J Pharmacol       Date:  2006-04-24       Impact factor: 8.739

3.  Prognostic significance of MST1R dysregulation in renal cell tumors.

Authors:  Ana S Pires-Luís; Márcia Vieira-Coimbra; Maria João Ferreira; João Ramalho-Carvalho; Pedro Costa-Pinheiro; Luís Antunes; Paula C Dias; Francisco Lobo; Jorge Oliveira; Inês Graça; Rui Henrique; Carmen Jerónimo
Journal:  Am J Cancer Res       Date:  2016-08-01       Impact factor: 6.166

4.  Macrophage stimulating protein promotes liver metastases of small cell lung cancer cells by affecting the organ microenvironment.

Authors:  Seidai Sato; Masaki Hanibuchi; Takuya Kuramoto; Nodoka Yamamori; Hisatsugu Goto; Hirohisa Ogawa; Atsushi Mitsuhashi; Trung The Van; Soji Kakiuchi; Shin-ichi Akiyama; Yasuhiko Nishioka; Saburo Sone
Journal:  Clin Exp Metastasis       Date:  2012-09-26       Impact factor: 5.150

5.  Knockdown of RON inhibits AP-1 activity and induces apoptosis and cell cycle arrest through the modulation of Akt/FoxO signaling in human colorectal cancer cells.

Authors:  Cho-Yun Chung; Young-Lan Park; Young-A Song; Eun Myung; Kyu-Yeol Kim; Gi-Hoon Lee; Ho-Seok Ki; Kang-Jin Park; Sung-Bum Cho; Wan-Sik Lee; Young-Do Jung; Kyung-Keun Kim; Young-Eun Joo
Journal:  Dig Dis Sci       Date:  2011-09-08       Impact factor: 3.199

6.  Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors.

Authors:  Patricia M LoRusso; Mrinal Gounder; Shadia I Jalal; Valérie André; Siva Rama Prasad Kambhampati; Nick Loizos; Jennifer Hall; Timothy R Holzer; Aejaz Nasir; Jan Cosaert; John Kauh; E Gabriela Chiorean
Journal:  Invest New Drugs       Date:  2017-02-04       Impact factor: 3.850

7.  Macrophage stimulating protein (MSP) evokes superoxide anion production by human macrophages of different origin.

Authors:  S Brunelleschi; L Penengo; L Lavagno; C Santoro; D Colangelo; I Viano; G Gaudino
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

Review 8.  Met-related receptor tyrosine kinase Ron in tumor growth and metastasis.

Authors:  Purnima K Wagh; Belinda E Peace; Susan E Waltz
Journal:  Adv Cancer Res       Date:  2008       Impact factor: 6.242

9.  Ron receptor tyrosine kinase negatively regulates TNFalpha production in alveolar macrophages by inhibiting NF-kappaB activity and Adam17 production.

Authors:  Nikolaos M Nikolaidis; Jerilyn K Gray; Devikala Gurusamy; William Fox; William D Stuart; Nathan Huber; Susan E Waltz
Journal:  Shock       Date:  2010-02       Impact factor: 3.454

10.  Ron tyrosine kinase receptor synergises with EGFR to confer adverse features in head and neck squamous cell carcinoma.

Authors:  J Keller; A S Nimnual; K R Shroyer; C Joy; I Ischenko; C S Chandler; L M Dong; M J Hayman; E L Chan
Journal:  Br J Cancer       Date:  2013-06-25       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.